Pacira BioSciences Profit Margin

The latest profit margin for PCRX is 6.25% as of June 2026. That compares with -18.06% in the prior-year period — up 134.6% year over year. That is below the Healthcare sector average of 14.34%. Investors often review this figure alongside Pacira BioSciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, PCRX's profit margin moved from -18.06% to 6.25% — a 134.6% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Pacira BioSciences's valuation or profitability profile.

Against Healthcare companies, PCRX currently prints 6.25% for profit margin, while the sector average sits near 14.34%. That is roughly 56.4% below the sector mean. Large gaps often invite a closer look at Pacira BioSciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Pacira BioSciences converts resources into returns. At 6.25%, PCRX may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -18.06% in the prior-year period — up 134.6% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting PCRX's profit margin (6.25%), review year-over-year change from -18.06%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.